Ziyuglycoside II suppressed the progression of osteosarcoma by coordinating estrogen-related receptor gamma and p53 signaling pathway

Abstract

Osteosarcoma (OS) is the most prevalent primary malignant bone tumor affecting children and adolescents. Despite ongoing research efforts, the 5-year survival rate has remained stagnant for many years, highlighting the critical need for novel drug development to enhance current treatment protocols. Ziyuglycoside II (ZYG II), a triterpenoid saponin extracted from S. officinalis, has recently demonstrated antitumor properties. This study evaluates the antitumor effect of ZYG II on osteosarcoma and elucidates its mechanism of action through the co-regulation of p53 and estrogen-related receptor gamma (ESRRG), which inhibits disease progression. The research employs in vitro experiments using multiple established osteosarcoma cell lines, as well as in vivo studies utilizing a nude mouse model of orthotopic xenograft osteosarcoma. Additionally, ESRRG shRNA was used to construct stable ESRRG-reducing OS cell lines to investigate the molecular mechanism by which ZYG II exerts its anti-osteosarcoma effects through the co-regulation of ESRRG and p53. Results indicate that ZYG II administration led to decreased OS cell viability and reduced tumor volumes. Furthermore, cell cycles were arrested at the G₀/G₁ phase, while the proportion of apoptotic cells increased. Expression of p53, ESRRG, p21, Bax, Cleaved Caspase-9, and Cleaved Caspase-3 proteins increased, while expression of CDK4, Cyclin D1, and Bcl-2 proteins decreased. Multiple ZYG II and ESRRG docking patterns were simulated through molecular docking. Comparing the pharmacodynamic response of ZYG II to OS cell lines with reduced ESRRG and normal expression demonstrated that ZYG II inhibits osteosarcoma progression, induces cell cycle arrest, and promotes cell apoptosis through the coordination of p53 and ESRRG. In conclusion, ZYG II inhibits osteosarcoma progression, leads to cell cycle arrest, and promotes cell apoptosis through synergistic regulation of p53 and ESRRG.

Keywords

Ziyuglycoside II / Osteosarcoma / Cell cycle arrest / p53 / Estrogen-related receptor gamma

References

[1] Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023; 73(1):17-48. https://doi.org/10.3322/caac.21763.

[2] Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(12):1520-1536. https://doi.org/10.1016/j.annonc.2021.08.1995.

[3] Pin F, Prideaux M, Bonewald LF, et al. Osteocytes and cancer. Curr Osteoporos Rep. 2021; 19(6):616-625. https://doi.org/10.1007/s11914-021-00712-9.

[4] Cole S, Gianferante DM, Zhu B, et al. Osteosarcoma: a surveillance, epidemiology, and end results program-based analysis from 1975 to 2017. Cancer-Am Cancer Soc. 2022; 128(11):2107-2118.

[5] Zhao X, Wu Q, Gong X, et al. Osteosarcoma: a review of current and future therapeutic approaches. Biomed Eng Online. 2021; 20(1):24. https://doi.org/10.1186/s12938-021-00860-0.

[6] Da W, Tao Z, Meng Y, et al. A 10-year bibliometric analysis of osteosarcoma and cure from 2010 to 2019. BMC Cancer. 2021; 21(1):115. https://doi.org/10.1186/s12885-021-07818-4.

[7] Beird HC, Bielack SS, Flanagan AM, et al. Osteosarcoma. Nat Rev Dis Primers. 2022; 8(1):77. https://doi.org/10.1038/s41572-022-00409-y.

[8] Gerstung M, Jolly C, Leshchiner I, et al. The evolutionary history of 2, 658 cancers. Nature. 2020; 578(7793):122-128. https://doi.org/10.1038/s41586-019-1907-7.

[9] Tobeiha M, Rajabi A, Raisi A, et al. Potential of natural products in osteosarcoma treatment: focus on molecular mechanisms. Biomed Pharmacother. 2021;144:112257. https://doi.org/10.1016/j.biopha.2021.112257.

[10] Kazantseva L, Becerra J, Santos-Ruiz L. Traditional medicinal plants as a source of inspiration for osteosarcoma therapy. Molecules. 2022; 27(15):5008. https://doi.org/10.3390/molecules27155008.

[11] Engeland K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 2022; 29(5):946-960. https://doi.org/10.1038/s41418-022-00988-z.

[12] Sanchez-Rivera FJ, Ryan J, Soto-Feliciano YM, et al. Mitochondrial apoptotic priming is a key determinant of cell fate upon p53 restoration. P Natl Acad Sci USA. 2021; 118(23):e2019740118. https://doi.org/10.1073/pnas.2019740118.

[13] Zhou P, Li J, Chen Q, et al. A comprehensive review of genus Sanguisorba: traditional uses, chemical constituents and medical applications. Front Pharmacol. 2021;12:750165. https://doi.org/10.3389/fphar.2021.750165.

[14] Motoc ACT, Kokeric T, Tripon S, et al. Sanguisorba minor Scop.: an overview of its phytochemistry and biological effects. Plants-Basel. 2023; 12(11):2128. https://doi.org/10.3390/plants12112128.

[15] Jang E, Inn KS, Jang YP, et al. Phytotherapeutic activities of Sanguisorba officinalis and its chemical constituents: a review. Am J Chin Med. 2018; 46(2):299-318. https://doi.org/10.1142/S0192415X18500155.

[16] Zhong Y, Li XY, Zhou F, et al. Ziyuglycoside II inhibits the growth of digestive system cancer cells through multiple mechanisms. Chin J Nat Med. 2021; 19(5):351-363. https://doi.org/10.1016/S1875-5364(21)60033-X.

[17] Zhu AK, Zhou H, Xia JZ, et al. Ziyuglycoside II-induced apoptosis in human gastric carcinoma BGC-823 cells by regulating Bax/Bcl-2 expression and activating caspase-3 pathway. Braz J Med Biol Res. 2013; 46(8):670-675. https://doi.org/10.1590/1414-431X20133050.

[18] Lkhagvasuren K, Kim JK. Ziyuglycoside II induces caspases-dependent and caspases-independent apoptosis in human colon cancer cells. Toxicol In Vitro. 2019; 59:255-262. https://doi.org/10.1016/j.tiv.2019.04.028.

[19] Liao W, Fan L, Zheng Z, et al. Ziyuglycoside II exerts antiproliferative and antimetastasis effects on hepatocellular carcinoma cells. Anticancer Drugs. 2020; 31(8):819-827. https://doi.org/10.1097/CAD.0000000000000918.

[20] Zhu X, Wang K, Zhang K, et al. Ziyuglycoside II inhibits the growth of human breast carcinoma MDA-MB-435 cells via cell cycle arrest and induction of apoptosis through the mitochondria dependent pathway. Int J Mol Sci. 2013; 14(9):18041-18055. https://doi.org/10.3390/ijms140918041.

[21] Zhu X, Wang K, Zhang K, et al. Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells. Toxicol Lett. 2014; 227(1):65-73. https://doi.org/10.1016/j.toxlet.2014.03.015.

[22] Wang K, Zou P, Zhu X, et al. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling. Toxicol In Vitro. 2019;61:104653. https://doi.org/10.1016/j.tiv.2019.104653.

[23] Fang H, Xie X, Liu P, et al. Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation. Biomed Pharmacother. 2020;132:110862. https://doi.org/10.1016/j.biopha.2020.110862.

[24] Chen X, Li B, Gao Y, et al. Saponins from Sanguisorba officinalis improve hematopoiesis by promoting survival through FAK and Erk1/2 activation and modulating cytokine production in bone marrow. Front Pharmacol. 2017;8:130. https://doi.org/10.3389/fphar.2017.00130.

[25] Nam SH, Lkhagvasuren K, Seo HW, et al. Antiangiogenic effects of ziyuglycoside II, a major active compound of Sanguisorba officinalis L. Phytother Res. 2017; 31(9):1449-1456. https://doi.org/10.1002/ptr.5874.

[26] Nakadai T, Shimada M, Ito K, et al. Two target gene activation pathways for orphan ERR nuclear receptors. Cell Res. 2023; 33(2):165-183. https://doi.org/10.1038/s41422-022-00774-z.

[27] Kim JH, Choi YK, Byun JK, et al.Estrogen-related receptor gamma is upregulated in liver cancer and its inhibition suppresses liver cancer cell proliferation via induction of p21 and p27. Exp Mol Med. 2016; 48(3):e213. https://doi.org/10.1038/emm.2015.115.

[28] Yu S, Wang X, Ng CF, et al. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer. Cancer Res. 2007; 67(10):4904-4914. https://doi.org/10.1158/0008-5472.CAN-06-3855.

[29] Kang MH, Choi H, Oshima M, et al. Estrogen-related receptor gamma functions as a tumor suppressor in gastric cancer. Nat Commun. 2018; 9(1):1920. https://doi.org/10.1038/s41467-018-04244-2.

[30] Field MG, Kuznetsoff JN, Zhang MG, et al. RB1 loss triggers dependence on ESRRG in retinoblastoma. Sci Adv. 2022; 8(33):eabm8466. https://doi.org/10.1126/sciadv.abm8466.

[31] Eichner LJ, Perry MC, Dufour CR, et al. miR-378^* mediates metabolic shift in breast cancer cells via the PGC-1β/ERRγ transcriptional pathway. Cell Metab. 2010; 12(4):352-361. https://doi.org/10.1016/j.cmet.2010.09.002.

[32] Su N, Qiu H, Chen Y, et al. miR-205 promotes tumor proliferation and invasion through targeting ESRRG in endometrial carcinoma. Oncol Rep. 2013; 29(6):2297-2302. https://doi.org/10.3892/or.2013.2400.

[33] Zirngibl RA, Chan JS, Aubin JE. Divergent regulation of the Osteopontin promoter by the estrogen receptor-related receptors is isoform- and cell context dependent. J Cell Biochem. 2013; 114(10):2356-2362. https://doi.org/10.1002/jcb.24583.

[34] Cardelli M, Auin JE. ERRγ is not required for skeletal development but is a RUNX2-dependent negative regulator of postnatal bone formation in male mice. PLoS One. 2014; 9(10):e109592. https://doi.org/10.1371/journal.pone.0109592.

[35] Kim HJ, Yoon HJ, Lee DK, et al. The estrogen-related receptor gamma modulator, GSK5182, inhibits osteoclast differentiation and accelerates osteoclast apoptosis. BMB Rep. 2021; 54(5):266-271. https://doi.org/10.5483/BMBRep.2021.54.5.243.

[36] Higuchi T, Sugisawa N, Miyake K, et al. The combination of olaratumab with doxorubicin and cisplatinum regresses a chemotherapy-resistant osteosarcoma in a patient-derived orthotopic xenograft mouse model. Transl Oncol. 2019; 12(9):1257-1263. https://doi.org/10.1016/j.tranon.2019.06.002.

[37] Li ZF, Zhou MY, Tan T, et al. A sample and sensitive HPLC-MS/MS method for simultaneous determination of ziyuglycoside I and its metabolite ziyuglycoside II in rat pharmacokinetics. Molecules. 2018; 23(3):543. https://doi.org/10.3390/molecules23030543.

[38] Elekofehinti OO, Iwaloye O, Olawale F, et al. Saponins in cancer treatment: current progress and future prospects. Pathophysiology. 2021; 28(2):250-272. https://doi.org/10.3390/pathophysiology28020017.

[39] Lan HR, Zhang YN, Han YJ, et al. Multifunctional nanocarriers for targeted drug delivery and diagnostic applications of lymph nodes metastasis: a review of recent trends and future perspectives. J Nanobiotechnol. 2023; 21(1):247. https://doi.org/10.1186/s12951-023-01990-4.

[40] Lu KH, Lu PW, Lin CW, et al. Curcumin in human osteosarcoma: from analogs to carriers. Drug Discov Today. 2023; 28(2):103437. https://doi.org/10.1016/j.drudis.2022.103437.

[41] Bai C, Zhang Z, Zhou L, et al. Repurposing ziyuglycoside II against colorectal cancer via orchestrating apoptosis and autophagy. Front Pharmacol. 2020;11:576547. https://doi.org/10.3389/fphar.2020.576547.

[42] Borrero LJH, EI-Deiry WS. Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting. Biochim Biophys Acta Rev Cancer. 2021; 1876(1): 188556. https://doi.org/10.1016/j.bbcan.2021.188556.

[43] Boutelle AM, Attardi LD. p53 And tumor suppression: it takes a network. Trends Cell Biol. 2021; 31(4):298-310. https://doi.org/10.1016/j.tcb.2020.12.011.

[44] Vaddavalli PL, Schumacher B. The p53 network: cellular and systemic DNA damage responses in cancer and aging. Trends Genet. 2022; 38(6):598-612. https://doi.org/10.1016/j.tig.2022.02.010.

[45] Hafezi S, Rahmani M. Targeting BCL-2 in cancer: advances, challenges, and perspectives. Cancers (Basel). 2021; 13(6):1292. https://doi.org/10.3390/cancers13061292.

[46] Guo X, Yue L, Li M, et al. Nuclear receptor estrogen-related receptor gamma suppresses colorectal cancer aggressiveness by regulating Wnt/β-catenin signaling. Carcinogenesis. 2022; 43(9):865-873. https://doi.org/10.1093/carcin/bgac054.